Capricor’s manufacturing expansion and cost cuts come as it awaits an FDA decision on a Duchenne muscular dystrophy treatment, while senators seek safeguards for prediction markets tied to drug trials.
Capricor Therapeutics is spending more to prepare for a possible launch of its Duchenne muscular dystrophy treatment, even as it trims staff and slows investment in other programs ahead of a November 22 Food and Drug Administration decision.
The company’s third-quarter operating expenses rose 70% as it expanded manufacturing at its San Diego facility, BioSpace reported. Capricor described the facility as ready for an initial launch of deramiocel, a cell therapy under FDA review for Duchenne muscular dystrophy, a progressive disease that can severely limit mobility and shorten life.
At the same time, the company disclosed a 10% workforce reduction and slower spending on programs other than deramiocel. The decisions illustrate the financial wager involved in preparing a treatment before regulators have made a final call: manufacturing capacity and personnel must be in place if approval comes, but those commitments carry costs while the outcome remains uncertain.
The FDA’s November 22 target date, known as a PDUFA date, marks the agency’s expected deadline for action. It is not itself a guarantee of approval. The available reporting does not establish what the treatment’s price would be, how insurers would cover it, or what patient access would look like if the FDA authorizes it.
For families affected by Duchenne, regulatory action is only one step between a candidate therapy and treatment in a clinic. A decision would determine whether deramiocel may be marketed for the reviewed use; manufacturing, coverage and affordability would shape what follows. Capricor’s spending signals its expectation of possible demand, not proof of clinical benefit or a final agency judgment.
A separate policy dispute is drawing attention to the integrity of the evidence behind drug decisions. Sens. Angela Alsobrooks and Ron Wyden have asked Health and Human Services Secretary Robert F. Kennedy Jr. what safeguards address event contracts tied to clinical-trial results and FDA approvals, CNBC reported.
The senators requested HHS communications with prediction-market platforms, the Commodity Futures Trading Commission and agency staff, along with internal analyses of potential risks. Their questions include whether people with confidential information could trade on it, whether markets could distort trial participation, and whether financial incentives might affect researchers.
Those concerns matter because clinical trials depend on participants and researchers following protocols, and regulators rely on trial data when evaluating treatments. A market tied to a trial outcome could create incentives around information that is not yet public. The cited reporting does not establish that any trial was manipulated or that insider trading occurred; the senators are seeking information about the risks and the government’s response.
The two developments meet at a consequential point in the drug pipeline. Companies must decide how much to invest before regulatory certainty, while patients and the public depend on trustworthy evidence to assess whether a treatment’s benefits justify its costs. Those are different questions from whether a company can manufacture a product or whether a market can offer a contract on an outcome.
Neither report provides a forecast of deramiocel’s eventual price or a specific account of HHS safeguards already in place. Those gaps leave key questions unresolved: how any approved therapy would be financed, and what protections ensure that financial speculation does not compromise the process used to judge treatments.
The FDA decision expected later this month will address the application before it. The senators’ inquiry asks HHS to account for the surrounding market activity. For patients, the value of a new therapy depends not only on a regulator’s decision, but also on credible evidence and a workable path to access.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.